William B White

List of Publications by Citations

Source: https://exaly.com/author-pdf/1886410/william-b-white-publications-by-citations.pdf

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

9,593
citations

44
g-index

206
ext. papers

207
ext. citations

44
g-index

6.22
ext. citations

avg, IF

L-index

#	Paper	IF	Citations
196	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858
195	Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 14-26	2.3	588
194	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015 , 385, 2067-76	40	551
193	Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. <i>New England Journal of Medicine</i> , 2018 , 378, 1200-1210	59.2	382
192	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018 , 72, e53-e90	8.5	333
191	Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 262-75.e9		296
190	Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. <i>Hypertension</i> , 2003 , 41, 1021-6	8.5	242
189	Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. <i>American Journal of Cardiology</i> , 2002 , 89, 425-30	3	197
188	Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension</i> , 2011 , 57, 413-20	8.5	167
187	Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. American Journal of Cardiology, 2003 , 92, 411-8	3	158
186	Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. <i>American Journal of Cardiology</i> , 2007 , 99, 91-8	3	151
185	EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. <i>American Heart Journal</i> , 2011 , 162, 620-626.e1	4.9	123
184	Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension, 2002, 39, 929-34	8.5	123
183	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 1540-1550	40	118
182	Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. <i>Blood Pressure Monitoring</i> , 2001 , 6, 63-72	1.3	117
181	The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 81-8	2.3	111
180	Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2003 , 92, 38-42	3	102

(2008-2006)

179	Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. <i>Hypertension</i> , 2006 , 48, 246-53	8.5	96	
178	Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. <i>American Journal of Hypertension</i> , 2004 , 17, 347-53	2.3	95	
177	Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. <i>Hypertension</i> , 2014 , 64, 731-7	8.5	92	
176	Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 462-8		91	
175	Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. <i>Circulation</i> , 2011 , 124, 2312-9	16.7	90	
174	Ambulatory blood-pressure monitoring in clinical practice. <i>New England Journal of Medicine</i> , 2003 , 348, 2377-8	59.2	90	
173	Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. <i>Circulation</i> , 2005 , 112, 1979-84	16.7	89	
172	Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. <i>American Journal of Hypertension</i> , 1999 , 12, 50S-55S	2.3	86	
171	Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 467-72	2.3	85	
170	Cardiovascular effects of the cyclooxygenase inhibitors. <i>Hypertension</i> , 2007 , 49, 408-18	8.5	85	
169	Long-term reproducibility of ambulatory blood pressure. <i>Journal of Hypertension</i> , 1994 , 12, 703???708	1.9	81	
168	Matching the circadian rhythms of hypertension with pharmacotherapy. <i>Clinical Cardiology</i> , 2009 , 26, 10-15	3.3	78	
167	The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. <i>Drug Safety</i> , 2015 , 38, 33-54	5.1	75	
166	Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. <i>Chest</i> , 2013 , 144, 756	8 <i>-</i> 7 . 6 5	72	
165	When and how to use self (home) and ambulatory blood pressure monitoring. <i>Journal of the American Society of Hypertension</i> , 2010 , 4, 56-61		69	
164	Early morning hypertension: what does it contribute to overall cardiovascular risk assessment?. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 397-402		57	
163	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. <i>American Journal of Therapeutics</i> , 2004 , 11, 244-50	1	57	
162	ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 850-5	2.3	55	

161	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. <i>American Heart Journal</i> , 2006 , 151, 176-84	4.9	55
160	Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. <i>Hypertension</i> , 2012 , 60, 310-8	8.5	51
159	Importance of blood pressure control over a 24-hour period. <i>Journal of Managed Care Pharmacy</i> , 2007 , 13, 34-9		50
158	Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). <i>Circulation</i> , 2019 , 140, 1626-1635	16.7	49
157	Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion. <i>American Journal of Cardiology</i> , 2003 , 92, 1439-41	3	49
156	A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. <i>American Heart Journal</i> , 2012 , 163, 27-32	4.9	47
155	Chronotherapeutics for cardiovascular disease. <i>Drugs</i> , 1998 , 55, 631-43	12.1	46
154	Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application. <i>Journal of Hypertension</i> , 2019 , 37, 905-916	1.9	45
153	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1633-1642	15.1	44
152	Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 43-8	6.1	44
151	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). <i>Circulation</i> , 2017 , 135, 1911-1921	16.7	43
150	Relevance of blood pressure variation in the circadian onset of cardiovascular events. <i>Journal of Hypertension</i> , 2003 , 21, S9-15	1.9	43
149	Utilizing ambulatory blood pressure recordings to evaluate antihypertensive drug therapy. <i>American Journal of Cardiology</i> , 1992 , 69, 8E-12E	3	43
148	Rapid buildup of brain white matter hyperintensities over 4 years linked to ambulatory blood pressure, mobility, cognition, and depression in old persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013 , 68, 1387-94	6.4	42
147	Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 765-75	2.3	42
146	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 664-671	6.7	41
145	Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. <i>American Journal of Cardiology</i> , 2009 , 104, 840-5	;3	41
144	Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. <i>American Heart Journal</i> , 2012 , 164, 14-20	4.9	40

(2007-2007)

143	Smoking-related morbidity and mortality in the cardiovascular setting. <i>Preventive Cardiology</i> , 2007 , 10, 1-4		39
142	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , 2016 , 39, 1267-73	14.6	38
141	Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 743-57		38
140	Methods of blood pressure determination to assess antihypertensive agents: are casual measurements enough?. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 581-6	6.1	38
139	Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 284-92	2.3	37
138	Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. <i>Blood Pressure Monitoring</i> , 2010 , 15, 205-12	1.3	37
137	Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 60-4	6.1	37
136	Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 626-33	2.3	35
135	A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	32
134	INtensive versus standard ambulatory blood pressure lowering to prevent functional Decline in the Elderly (INFINITY). <i>American Heart Journal</i> , 2013 , 165, 258-265.e1	4.9	32
133	Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. <i>Blood Pressure Monitoring</i> , 2005 , 10, 157-	·6 3 3	31
132	Renal denervation therapy for hypertension: pathways for moving development forward. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 341-50		29
131	Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 387-90	6.1	29
130	History and Justification of a National Blood Pressure Measurement Validated Device Listing. <i>Hypertension</i> , 2019 , 73, 258-264	8.5	29
129	Defining the problem of treating the patient with hypertension and arthritis pain. <i>American Journal of Medicine</i> , 2009 , 122, S3-9	2.4	28
128	Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2013 , 165, 477-88	4.9	27
127	Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. <i>American Journal of Medicine</i> , 2008 , 121, S2-7	2.4	27
126	Cardiovascular risk, hypertension, and NSAIDs. <i>Current Rheumatology Reports</i> , 2007 , 9, 36-43	4.9	26

125	Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. <i>Blood Pressure Monitoring</i> , 2008 , 13, 21-7	1.3	25
124	Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. <i>American Heart Journal</i> , 2004 , 148, 628-34	4.9	25
123	Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. <i>American Journal of Hypertension</i> , 2001 , 14, 942-9	2.3	25
122	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , 2016 , 34, 788-	- ∮ -₽	24
121	Functional reach of older adults: normative reference values based on new and published data. <i>Physiotherapy</i> , 2017 , 103, 387-391	3	22
120	Ambulatory blood pressure monitoring in the 21st century. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1108-1111	2.3	21
119	Update on the drug treatment of hypertension in patients with cardiovascular disease. <i>American Journal of Medicine</i> , 2005 , 118, 695-705	2.4	21
118	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 200-5	6.4	21
117	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015 , 169, 486-95	4.9	20
116	Cardiovascular Effects of Incretin-Based Therapies. <i>Annual Review of Medicine</i> , 2016 , 67, 245-60	17.4	20
115	Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2008 , 13, 123-9	1.3	20
114	Clinical trial experience around the globe: focus on calcium-channel blockers. <i>Clinical Cardiology</i> , 2003 , 26, II7-11	3.3	20
113	The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 173-8	6.1	20
112	Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Journal of the American Society of Hypertension, 2016 , 10, 755-762		20
111	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 962-969	6.7	19
110	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 ,	6.7	19
109	Systolic versus diastolic blood pressure versus pulse pressure. <i>Current Cardiology Reports</i> , 2002 , 4, 463-7	74.2	19
108	Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. <i>American Journal of Hypertension</i> , 2001 , 14, 1239-47	2.3	19

107	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 398-405	6.9	18
106	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016 , 68, 606-13	8.5	18
105	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015 , 169, 197-204	4.9	18
104	Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. Journal of Clinical Hypertension, 2011 , 13, 506-16	2.3	18
103	Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. <i>Journal of Clinical</i>	2.3	18
102	Hypertension, 2008, 10, 450-8 Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 819-	-826	18
101	Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. <i>Hypertension</i> , 2008 , 52, 587-93	8.5	17
100	Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. <i>American Journal of Nephrology</i> , 2018 , 48, 172-180	4.6	17
99	Chronopharmacology of cardiovascular therapy. Blood Pressure Monitoring, 2002, 7, 199-207	1.3	16
98	Managing hypertension with ambulatory blood pressure monitoring. <i>Current Cardiology Reports</i> , 2015 , 17, 2	4.2	15
97	Effects of naproxcinod on blood pressure in patients with osteoarthritis. <i>American Journal of Cardiology</i> , 2011 , 107, 1338-45	3	15
96	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 1742-1767	1.9	15
95	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018 , 131, 813-819.e5	2.4	14
94	Review of the state of renal nerve ablation for patients with severe and resistant hypertension. Journal of the American Society of Hypertension, 2013 , 7, 484-93		14
93	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , 2017 , 119, 1111-1115	3	13
92	Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 768-778.e1		13
91	Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1701-1710	6.9	13
90	Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , 2014 , 16, 541	4.2	13

89	Cardiovascular risk, hypertension, and NSAIDs. Current Pain and Headache Reports, 2007, 11, 428-35	4.2	13
88	"Inappropriate" physician habits in prescribing oral nifedipine capsules in hospitalized patients. American Journal of Hypertension, 1996 , 9, 1035-9	2.3	13
87	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009114	6	13
86	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , 2018 , 41, 1510-1515	14.6	13
85	Thalamic fractional anisotropy predicts accrual of cerebral white matter damage in older subjects with small-vessel disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014 , 34, 1321-7	7.3	12
84	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e012797	6	12
83	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019 , 218, 66-74	4.9	12
82	Cardiovascular Safety of the 🛮 Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1084-1091	2.9	11
81	Timed mobility: description of measurement, performance, and dimensionality among older adults. <i>Disability and Rehabilitation</i> , 2018 , 40, 2011-2014	2.4	11
80	Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?. <i>Current Hypertension Reports</i> , 2012 , 14, 366-73	4.7	11
79	Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 103-118	2.6	10
78	Clinical assessment of early morning blood pressure in patients with hypertension. <i>Preventive Cardiology</i> , 2007 , 10, 210-4		10
77	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1006-	1679	10
76	Relationships among clinic, home, and ambulatory blood pressures with small vessel disease of the brain and functional status in older people with hypertension. <i>American Heart Journal</i> , 2018 , 205, 21-30	4.9	9
75	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019 , 58, 61-69	3.9	9
74	Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. <i>Journal of Hypertension</i> , 2017 , 35, 761-768	1.9	9
73	Importance of aggressive blood pressure lowering when it may matter most. <i>American Journal of Cardiology</i> , 2007 , 100, 10J-16J	3	9
72	Treatment of benign prostatic hyperplasia in hypertensive men. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 212-7	2.3	9

71	Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. <i>American Journal of Hypertension</i> , 2003 , 16, 739-	-45 ³	9
70	Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 233-8	2.9	9
69	Accuracy and analysis of ambulatory blood pressure monitoring data. Clinical Cardiology, 1992, 15, II10-	33.3	9
68	Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 664-8	6.1	9
67	Longitudinal microstructural changes of cerebral white matter and their association with mobility performance in older persons. <i>PLoS ONE</i> , 2018 , 13, e0194051	3.7	9
66	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1462-1471	12.3	8
65	Cardiovascular Safety of the Selective Expioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 309-317	2.6	8
64	Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 20-7		8
63	Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 876-82	2.3	8
62	Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. <i>American Heart Journal</i> , 2002 , 144, 657-65	4.9	8
61	Effects of a State- and Use-Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 90-97	2.9	7
60	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 780-90		7
59	Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 25-30	2.3	7
58	The role of ambulatory monitoring of the blood pressure for assessment of antihypertensive agents. <i>Journal of Clinical Pharmacology</i> , 1992 , 32, 524-8	2.9	7
57	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 382-391	3	7
56	Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	7
55	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 695-701	2.3	6
54	Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 332-340	2.3	6

53	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> ,	4.9	6
52	2016 , 175, 18-27 Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 397-403	2.3	6
51	Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 910-6	2.3	6
50	Severe, accelerated postpartum hypertension associated with hyperthyroxinaemia. Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1986 , 93, 1297-9	3.7	6
49	Ejaculatory failure and urinary dysfunction secondary to labetalol. <i>Journal of Urology</i> , 1988 , 139, 371-2	2.5	6
48	Cardiovascular safety of therapies for type 2 diabetes. Expert Opinion on Drug Safety, 2017, 16, 13-25	4.1	5
47	Diagnostic evaluation: Ambulatory blood pressure monitoring in clinical hypertension management. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 939-41; quiz 942		5
46	Effects of metoprolol succinate extended release vs. amlodipine besylate on the blood pressure, heart rate, and the rate-pressure product in patients with hypertension. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 378-84		5
45	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1580-1587	6.7	5
44	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. <i>Blood Pressure Monitoring</i> , 2018 , 23, 153-163	1.3	4
43	Clinical utility of ambulatory blood pressure: perspectives for national insurance coverage. <i>Blood Pressure Monitoring</i> , 2002 , 7, 27-31	1.3	4
42	Effects of the oral testosterone undecanoate KyzatrexIbn ambulatory blood pressure in hypogonadal men. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 1420-1430	2.3	4
41	Exposure to Racial Discrimination and Ambulatory Blood Pressure in Women with Type 2 Diabetes. <i>Stress and Health</i> , 2016 , 32, 337-345	3.7	4
40	Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. <i>Sub-Cellular Biochemistry</i> , 2007 , 42, 145-58	5.5	4
39	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. <i>Clinical Cardiology</i> , 2018 , 41, 1022-1027	3.3	3
38	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018 , 122, 1496-1505	3	3
37	Leadership message. American Society of Hypertension-designated centers of excellence: a new initiative. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 391-2	2.3	3
36	The potential role of nitric oxide in cardiovascular safety when treating patients with osteoarthritis and hypertension: a moderated panel discussion. <i>American Journal of Medicine</i> , 2009 , 122, S23-5	2.4	3

(2022-2003)

35	OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003 , 16, A11	2.3	3
34	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1612-1624	6.1	3
33	Cardiovascular Safety of Febuxostat. New England Journal of Medicine, 2018, 379, 1584	59.2	3
32	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 947-956	1.9	2
31	Response to Letter to the Editor by Blankfield regarding "Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.". <i>American Heart Journal</i> , 2013 , 166, e11	4.9	2
30	Pharmacologic agents in the management of hypertensionnisoldipine coat-core. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 259-66	2.3	2
29	Ambulatory blood pressure monitoring: technique and application in the study of cardiac dysfunction and congestive heart failure. <i>Congestive Heart Failure</i> , 2001 , 7, 319-324		2
28	Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. <i>Blood Pressure Monitoring</i> , 2021 , 27,	1.3	2
27	Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 1473-1476	1.2	2
26	Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 630-637	2.6	2
25	Severe and refractory hypertension in a young woman. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 506-9		2
24	Comparative effects of telmisartan in the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , 2002 , 4, 20-5	2.3	2
23	EXAMINE: targeting risk and treatment in diabetes - AuthorsPreply. Lancet, The, 2015, 386, 1445	40	1
22	Cardiovascular risk and ambulatory blood pressure. Current Hypertension Reports, 1999 , 1, 509-11	4.7	1
21	Ambulatory Blood Pressure Monitoring in Older Persons 2016 , 209-225		1
20	Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , 2021 , 20, 187	8.7	1
19	Hypertension management: differing points of view: ambulatory blood pressure monitoring for every hypertensive patient: itB about time!: the argument against. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 710-3; quiz 714	2.3	1
18	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease <i>Postgraduate Medicine</i> , 2022 ,	3.7	1

17	Severe and resistant hypertension in an older woman with claudication. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 475-479		O
16	Home blood pressure monitoring as an intervention to control hypertension: comment on "Home blood pressure management and improved blood pressure control". <i>Archives of Internal Medicine</i> , 2011 , 171, 1181-2		Ο
15	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , 2021 , 1-8	4.6	0
14	Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1407-1409	6.9	O
13	Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial <i>Kidney360</i> , 2021 , 2, 425-434	1.8	0
12	Foreword. The 20th year of Blood Pressure Monitoring. <i>Blood Pressure Monitoring</i> , 2015 , 20, 1	1.3	
11	Response to Letter Regarding Article, "Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY)". <i>Circulation</i> , 2020 , 141, e6	52 ¹⁶ 75:	3
10	Management of Hypertension in Athletes 2018 , 49-67		
9	The present and future of the American Society of Hypertension-2012. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 401-3	2.3	
8	The present and future of the American Society of Hypertension: 2012. <i>Journal of the American Society of Hypertension</i> , 2012 , 6, 237-9		
7	Response. <i>Chest</i> , 2013 , 144, 1082-1083	5.3	
6	Blood Pressure Monitoring enters its 14th year. <i>Blood Pressure Monitoring</i> , 2009 , 14, 1	1.3	
5	Comments on the Study of Zannad et al. American Journal of Hypertension, 1997, 10, 1190	2.3	
4	Acute pain in the tip of the index finger. American Journal of Medicine, 2005, 118, 1223-4	2.4	
3	The Silver Anniversary of Blood Pressure Monitoring. <i>Blood Pressure Monitoring</i> , 2020 , 25, 1	1.3	
2	Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - AuthorsPreply. Lancet, The, 2020 , 396, 311-312	40	
1	Module 1: Historical review of evidence-based treatment of hypertension. <i>Journal of Family Practice</i> , 2012 , 61, S5-14; quiz S27	0.2	